medcelerator · clinician one-pager

New Heart-Protection Use for Mounjaro in Type 2 Diabetes

Mounjaro (tirzepatide) — weekly shot for adults with type 2 diabetes that now also carries a labelled heart-protection use

FDA Approved · United States · September 11, 2026

Condition: Type 2 Diabetes

Who this is for

This is for adults with type 2 diabetes who are at high risk for heart attack, stroke, or cardiovascular death, and who may already be candidates for weekly Mounjaro for blood sugar — now with a labelled US heart-protection indication based on SURPASS-CVOT. It explains the August 2026 FDA expansion, the noninferiority result versus dulaglutide, boxed thyroid warnings, Lilly contacts, and how to talk with a diabetes / heart clinician — without treating “as good as Trulicity on MACE” as “proven better,” collapsing the obesity label (Zepbound) into this pathway, a DIY import as a plan, or “approved” as funded. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/mounjaro-tirzepatide-cv